A virus-like particle vaccine can prime the body’s immune response and prevent the severe respiratory disease that results when patients given an early form of a vaccine for respiratory syncytial virus (RSV) are exposed to RSV, according to a study.
A virus-like particle vaccine can prime the body’s immune response and prevent the severe respiratory disease that results when patients given an early form of a vaccine for respiratory syncytial virus (RSV) are exposed to RSV, according to a study.